Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Nidlegy™ Phase III PIVOTAL trial meets the study's primary objective

Posted On: 2023-10-17 07:14:20 (Time Zone: IST)


Philogen S.p.A. (BIT:PHIL) and Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) are pleased to announce positive results from the Phase III PIVOTAL trial in patients with locally advanced fully resectable melanoma (NCT02938299). The study compared neoadjuvant intratumoral Nidlegy™ (Daromun) followed by surgery (treatment arm) vs. surgery alone (control arm). Patients were allowed to receive approved adjuvant systemic therapies after surgery in both arms.

According to the protocol, the primary endpoint of the study was the Recurrence-Free Survival (RFS) assessed per Blinded Independent Central Review (BICR) for patients treated with Nidlegy™, compared to the control arm. At median follow-up of 27.6 months in both groups, the study met its primary endpoint with a statistically significant and clinically meaningful improvement in RFS of the treatment arm compared to the control arm. This positive outcome was consistently in line with the Investigators' Assessment: a significant reduction of the hazard risk ratio of 33% (HR = 0.67) and 37% (HR = 0.63), respectively, favoring the treatment arm, was observed both in the BICR and in the Investigators' Assessment analysis.

Treatment-related adverse events observed with Nidlegy™ were benign and manageable, consistent with the proposed mechanism of action and with the favorable safety profile previously reported in the Phase II study [Danielli et al. (2015) Cancer Immunol. Immunother., 64, 999]. Grade 3 adverse events occurred in 24.8% of the treated patients. Neither grade 4 toxicity nor treatment-related deaths were observed in the study. Nidlegy™ treatment was not associated with the induction of autoimmune conditions.

PIVOTAL enrolled 257 patients in Europe across 22 clinical centers in Germany, Italy, France and Poland. The results, including sub-group analyses, will be presented at a forthcoming medical meeting.

Nidlegy™ is also being developed in dedicated Phase II clinical trials for the treatment of aggressive forms of non-melanoma skin cancer, including high-risk locally advanced basal cell carcinoma and cutaneous squamous cell carcinoma.

Prof. Dario Neri, co-founder, CEO and CSO of Philogen, commented: "We are extremely pleased to announce positive topline data emerging from our PIVOTAL program in locally advanced resectable melanoma. The clinical data in melanoma and high-risk non melanoma skin cancers bode well for the possible adoption of intralesional Nidlegy™ in a series of Dermato-Oncology indications. Philogen is currently executing six additional advanced clinical trials with registration potential featuring either Nidlegy™ or Fibromun, the company's most advanced product candidates, as active ingredients."

Alfredo Covelli, MD, Chief Medical Officer of Philogen, commented: "Neoadjuvant cytokine therapy for the treatment of locally advanced skin cancers enables a robust expansion of tumorinfiltrating lymphocytes. By anchoring interleukin-2 and tumor necrosis factor within the tumor mass through the L19 antibody moiety, we minimize systemic side effects while mounting a systemic robust anti-cancer immune response. This Phase 3 study merged the intralesional approach with IL2, pioneered by Prof. Claus Garbe more than 20 years ago, with the concepts of antibody-based tumor targeting, and with neoadjuvant therapy in locally advanced melanoma. The approach may find a broad applicability in different types of cancer."

Hellen De Kloet, Business Head - Western Europe and ANZ, Sun Pharma, said: "We are looking forward to commercializing Nidlegy™ in Europe, Australia and New Zealand as the first neoadjuvant immunotherapy for patients with resectable advanced melanoma. Nidlegy™, as an intralesional therapeutic option, addresses the existing significant unmet need for effective and well-tolerated treatments in patients, before undergoing surgery".

Philogen and Sun Pharma announced on May 30th, 2023, to have entered into distribution, license and supply agreement for commercializing Nidlegy™ in Europe, Australia and New Zealand for the treatment of skin cancers.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1134.90 as compared to the previous close of Rs. 1145.60. The total number of shares traded during the day was 28229 in over 1751 trades.

The stock hit an intraday high of Rs. 1147.25 and intraday low of 1134.00. The net turnover during the day was Rs. 32198570.00.


Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

HCLTech and Tecnotree collaborate to bring 5G-led GenAI solutions for telcos

Federal Bank Unveils UPI-Enabled RuPay Wave Credit Card via a Simplified 2-click onboarding journey

Lemon Tree Hotels signs a new property in Morbi, Gujarat

Allcheckdeals India Pvt Ltd to invest in NewInc Internet Services Pvt Ltd

Gensol Engineering Ltd allotted additional 250 MW (500 MWh) for GUVNL's Battery Energy Storage Project

APSEZ shines in World Bank's global container port rankings

Radico Khaitan's Luxury Brands Awarded Best World Whisky and Best Gin at the John Barleycorn Awards 2024

Brigade Group signs agreement to develop a Third World Trade Center Tower at Infopark Kochi

Avenue Supermarts Limited opens new store at Mettupalayam

TTK Prestige Limited signs agreement with consultant for future business strategy and plan

Raminfo Limited unveils new Logo, embarks on a Journey of Technological Transformation and Expansion

Eimco Elecon India Ltd receives order worth Rs. 33.11 crores

IndianOil and GPS Renewables Pvt. Ltd. form Joint Venture for Sustainable Energy Solutions

Smart Finsec Limited updates on corporate guarantee

ZF Group sells 7.5 percent stake of its holding in ZF Commercial Vehicle Control Systems India Limited

Vikas Lifecare Limited, plan support agreement for the acquisition of 100% of the equity of Ebix Inc.

Aayush Wellness Limited Board approved 10-for-1 Stock Split and ESOP

IM+ Capitals Ltd is now Fedders Holding Limited

Restaurant Brands Asia Limited approves investment in PT Sari Burger Indonesia

Lords Ishwar Hotels Ltd approves facility from Kotak Mahindra Bank

ABB India and Witt India partner to enhance safety and operational efficiency in key infrastructure projects

Project award for Valiant Cyber Security solutions by ONGC

Strategic partnership between Hubject and Exicom aims to fuel further growth in India's booming EV market

Bharti Airtel Ltd acquires ~26.95 million shares of Indus Towers Ltd

Vipul Organics Limited commences construction at Sayakha in Gujarat

Tata Motors announces price increase of its commercial vehicles from July 2024

Sprayking Limited secures major order for 25 Tonnes of Brass Rod worth Rs. 15 Million

HCLTech Grant symposium at Bhubaneswar discusses strategies and challenges in addressing poverty in rural India

HDFC Securities Caution customers against Fraudulent WhatsApp Groups and Impersonation Scams

Dynacons recognized as HPE Solution Provider of the Year 2024 by Hewlett Packard Enterprise

Apeejay Surrendra Park Hotels Ltd signs new hotel in Nainital, Uttarakhand

Netweb Unveils New AMD based Make-in-India Servers for Data Centers AI Systems

Muthoot Microfin Ltd receives IRDAI registration to act as Corporate Agent

Electronics Mart India Ltd opens Bajaj Electronics store at Tanuku, Andhra Pradesh

Tata Technologies collaborates with Microsoft and Tata Motors to drive innovation with the InnoVent hackathon for engineering students, focused on Generative AI

Sona BLW Precision Forgings Ltd receives certification under PLI scheme

NGL Fine-Chem Limited receives CEP from EDQM for TRICLABENDAZOLE

Libord Finance Limited reduces stake in Libord Brokerage Pvt Ltd

Lancer Container Lines Ltd receives 2nd batch of 100 new containers from SYMCON Industries Pvt Ltd

Artefact Projects Limited receives order from NHAI

Birla Opus Launches Its New Thematic Communication and embarks on a journey to 'Make Life Beautiful'!

Shree Rama Multi-Tech Limited commissions Multi-Layer Film plant

Kaycee Industries Ltd fixes July 6, 2024 as record date for stock split, bonus issue

UFO Moviez signs technology deal with Gofilex

Made in Bharat, for the World: MISH NOW LIVE IN EUROPE ON ZALANDO.COM and OTTO.COM

Jubilant Pharmova announces completion of USFDA audit of contract manufacturing facility at Montreal, Canada

Radico Khaitan brings internationally acclaimed Rampur Asava Indian Single Malt Whisky to Indian markets

DroneAcharya Aerial Innovations Ltd wins order from Maani Care System India Pvt Ltd

Cipla EU to invest an additional EUR 3 million in Ethris

Futuristic Solutions Limited recommends final dividend of Rs. 1


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020